{"id":745667,"date":"2018-09-11T05:45:00","date_gmt":"2018-09-11T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/"},"modified":"2025-11-07T01:27:03","modified_gmt":"2025-11-07T06:27:03","slug":"mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/","title":{"rendered":"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia"},"content":{"rendered":"<p class=\"bwalignc\">       Company Plans to Submit Supplemental New Drug Applications in the US        and EU     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States<br \/>\n      and Canada, today announced that the pivotal Phase 3 clinical study<br \/>\n      evaluating the company\u2019s antibiotic ZERBAXA<sup>\u00ae<\/sup> (ceftolozane and<br \/>\n      tazobactam) at an investigational dose for the treatment of adult<br \/>\n      patients with either ventilated hospital-acquired bacterial pneumonia<br \/>\n      (HABP) or ventilator-associated bacterial pneumonia (VABP) met the<br \/>\n      pre-specified primary endpoints, demonstrating non-inferiority to<br \/>\n      meropenem, the active comparator, in Day 28 all-cause mortality and in<br \/>\n      clinical cure rate at the test-of-cure visit. In the U.S., ZERBAXA is<br \/>\n      currently indicated in adult patients for the treatment of complicated<br \/>\n      urinary tract infections, including pyelonephritis, caused by certain<br \/>\n      Gram-negative microorganisms, and is indicated, in combination with<br \/>\n      metronidazole, in adult patients for the treatment of complicated<br \/>\n      intra-abdominal infections caused by certain Gram-negative and<br \/>\n      Gram-positive microorganisms.\n    <\/p>\n<p>\n      Based on these results, Merck plans to submit supplemental new drug<br \/>\n      applications to the U.S. Food and Drug Administration (FDA) and European<br \/>\n      Medicines Agency (EMA) seeking regulatory approval of ZERBAXA for this<br \/>\n      potential new indication. The company plans to submit results from the<br \/>\n      study for presentation at a future scientific conference.\n    <\/p>\n<p>\n      \u201cHABP and VABP are serious and life-threatening hospital related<br \/>\n      pulmonary infections, especially in patients with severe underlying<br \/>\n      medical conditions,\u201d said Dr. Roy Baynes, senior vice president, head of<br \/>\n      global clinical development and chief medical officer, Merck Research<br \/>\n      Laboratories. \u201cThe results from the ASPECT-NP study demonstrate the<br \/>\n      potential role of ZERBAXA for the treatment of patients with HABP and<br \/>\n      VABP.\u201d\n    <\/p>\n<p>\n      <b>About the ASPECT-NP study<\/b>\n    <\/p>\n<p>\n      This prospective, randomized, double-blind, multicenter,<br \/>\n      non-inferiority, Phase 3 study assessed the safety and efficacy of<br \/>\n      ZERBAXA compared with meropenem in 726 adult patients diagnosed with<br \/>\n      either ventilated HABP or VABP requiring intravenous antibiotic therapy.<br \/>\n      In the study, ZERBAXA was administered in an investigational 3g dose<br \/>\n      compared with meropenem 1g, each given intravenously every eight hours<br \/>\n      for 8 to 14 days, or for 14 days for <i>Pseudomonas aeruginosa<\/i><br \/>\n      infection. Meropenem is an approved broad-spectrum injectable antibiotic<br \/>\n      widely used to treat serious infections.\n    <\/p>\n<p>\n      Additional details about the study can be found online at <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02070757\" rel=\"nofollow\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02070757<\/a>.\n    <\/p>\n<p>\n      <b>About ZERBAXA (ceftolozane and tazobactam)<\/b>\n    <\/p>\n<p>\n      ZERBAXA is an antibacterial combination product for intravenous infusion<br \/>\n      consisting of the cephalosporin antibacterial drug ceftolozane sulfate<br \/>\n      and the beta-lactamase inhibitor tazobactam sodium.\n    <\/p>\n<p>\n      ZERBAXA 1.5g (ceftolozane 1g and tazobactam 0.5g) is approved in the<br \/>\n      United States and is indicated in adult patients for the treatment of<br \/>\n      complicated urinary tract infections (cUTI), including pyelonephritis,<br \/>\n      caused by the following Gram-negative microorganisms: <i>Escherichia coli<\/i>,<br \/>\n      <i>Klebsiella pneumoniae<\/i>, <i>Proteus mirabilis<\/i>, and <i>Pseudomonas<br \/>\n      aeruginosa<\/i>. ZERBAXA used in combination with metronidazole is<br \/>\n      indicated in adult patients for the treatment of complicated<br \/>\n      intra-abdominal infections (cIAI) caused by the following Gram-negative<br \/>\n      and Gram-positive microorganisms: <i>Enterobacter cloacae<\/i>, <i>Escherichia<br \/>\n      coli<\/i>, <i>Klebsiella oxytoca<\/i>, <i>Klebsiella pneumoniae<\/i>, <i>Proteus<br \/>\n      mirabilis<\/i>, <i>Pseudomonas aeruginosa<\/i>, <i>Bacteroides fragilis<\/i>,<br \/>\n      <i>Streptococcus anginosus<\/i>, <i>Streptococcus constellatus<\/i>, and <i>Streptococcus<br \/>\n      salivarius<\/i>.\n    <\/p>\n<p>\n      To reduce the development of drug-resistant bacteria and maintain the<br \/>\n      effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should<br \/>\n      be used only to treat infections that are proven or strongly suspected<br \/>\n      to be caused by susceptible bacteria. When culture and susceptibility<br \/>\n      information are available, they should be considered in selecting or<br \/>\n      modifying antibacterial therapy. In the absence of such data, local<br \/>\n      epidemiology and susceptibility patterns may contribute to the empiric<br \/>\n      selection of therapy.\n    <\/p>\n<p>\n      <b>Important Safety Information about ZERBAXA<\/b>\n    <\/p>\n<p>\n      <b>Patients with renal impairment:<\/b> Decreased efficacy of ZERBAXA has<br \/>\n      been observed in patients with baseline creatinine clearance (CrCl) of<br \/>\n      30 to \u226450 mL\/min. In a clinical trial, patients with cIAIs with CrCl &gt;50<br \/>\n      mL\/min had a clinical cure rate of 85.2% when treated with ZERBAXA<br \/>\n      (ceftolozane and tazobactam) plus metronidazole vs. 87.9% when treated<br \/>\n      with meropenem. In the same trial, patients with CrCl 30 to \u226450 mL\/min<br \/>\n      had a clinical cure rate of 47.8% when treated with ZERBAXA plus<br \/>\n      metronidazole vs. 69.2% when treated with meropenem. A similar trend was<br \/>\n      also seen in the cUTI trial. Monitor CrCl at least daily in patients<br \/>\n      with changing renal function and adjust the dose of ZERBAXA accordingly.\n    <\/p>\n<p>\n      <b>Hypersensitivity:<\/b> ZERBAXA is contraindicated in patients with<br \/>\n      known serious hypersensitivity to ceftolozane\/tazobactam,<br \/>\n      piperacillin\/tazobactam, or other members of the beta-lactam class.<br \/>\n      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions<br \/>\n      have been reported in patients receiving beta-lactam antibacterials.<br \/>\n      Before initiating therapy with ZERBAXA, make careful inquiry about<br \/>\n      previous hypersensitivity reactions to cephalosporins, penicillins, or<br \/>\n      other beta-lactams. If an anaphylactic reaction to ZERBAXA occurs,<br \/>\n      discontinue use and institute appropriate therapy.\n    <\/p>\n<p>\n      <i><br \/>\n<b>Clostridium difficile<\/b><br \/>\n<\/i><br \/>\n<b>\u2013associated diarrhea (CDAD),<\/b><br \/>\n      ranging from mild diarrhea to fatal colitis, has been reported with<br \/>\n      nearly all systemic antibacterial agents, including ZERBAXA. Careful<br \/>\n      medical history is necessary because CDAD has been reported to occur<br \/>\n      more than two months after the administration of antibacterial agents.<br \/>\n      If CDAD is confirmed, antibacterial use not directed against <i>C.<br \/>\n      difficile<\/i> should be discontinued, if possible.\n    <\/p>\n<p>\n      <b>Development of drug-resistant bacteria:<\/b> Prescribing ZERBAXA in<br \/>\n      the absence of a proven or strongly suspected bacterial infection is<br \/>\n      unlikely to provide benefit to the patient and increases the risk of the<br \/>\n      development of drug-resistant bacteria.\n    <\/p>\n<p>\n      <b>Adverse reactions:<\/b> The most common adverse reactions occurring in<br \/>\n      \u22655% of patients were headache (5.8%) in the cUTI trial, and nausea<br \/>\n      (7.9%), diarrhea (6.2%) and pyrexia (5.6%) in the cIAI trial.\n    <\/p>\n<p>\n      <b>Merck\u2019s commitment to infectious diseases<\/b>\n    <\/p>\n<p>\n      For more than 100 years, Merck has contributed to the discovery and<br \/>\n      development of novel medicines and vaccines to combat infectious<br \/>\n      diseases. In addition to a combined portfolio of antibiotic, antiviral<br \/>\n      and antifungal medicines, vaccines, and medicines for HIV and HCV, Merck<br \/>\n      has multiple programs that span discovery through late-stage<br \/>\n      development. Merck currently has eight compounds in Phase 2\/Phase 3<br \/>\n      clinical trials for the potential treatment or prevention of infectious<br \/>\n      diseases.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZERBAXA (ceftolozane and<br \/>\n      tazobactam) at <\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180911005151r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>Robert        Consalvo, 908-295-0928<br \/>or<br \/>Investors:<br \/>Michael DeCarbo,        908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study evaluating the company\u2019s antibiotic ZERBAXA \u00ae (ceftolozane and tazobactam) at an investigational dose for the treatment of adult patients with either ventilated hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) met the pre-specified primary endpoints, demonstrating non-inferiority to meropenem, the active comparator, in Day 28 all-cause mortality and in clinical cure rate at the test-of-cure visit. In the U.S., ZERBAXA is currently indicated in adult patients for the treatment of complicated urinary tract infections, including pyelonephritis, caused by certain Gram-negative microorganisms, and is indicated, in combination with metronidazole, in adult patients for the treatment of complicated intra-abdominal infections caused by certain Gram-negative and Gram-positive microorganisms. Based on these<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745667","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study evaluating the company\u2019s antibiotic ZERBAXA \u00ae (ceftolozane and tazobactam) at an investigational dose for the treatment of adult patients with either ventilated hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) met the pre-specified primary endpoints, demonstrating non-inferiority to meropenem, the active comparator, in Day 28 all-cause mortality and in clinical cure rate at the test-of-cure visit. In the U.S., ZERBAXA is currently indicated in adult patients for the treatment of complicated urinary tract infections, including pyelonephritis, caused by certain Gram-negative microorganisms, and is indicated, in combination with metronidazole, in adult patients for the treatment of complicated intra-abdominal infections caused by certain Gram-negative and Gram-positive microorganisms. Based on these\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\\\/\",\"name\":\"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-09-11T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:27:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia - Merck.com","og_description":"Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study evaluating the company\u2019s antibiotic ZERBAXA \u00ae (ceftolozane and tazobactam) at an investigational dose for the treatment of adult patients with either ventilated hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) met the pre-specified primary endpoints, demonstrating non-inferiority to meropenem, the active comparator, in Day 28 all-cause mortality and in clinical cure rate at the test-of-cure visit. In the U.S., ZERBAXA is currently indicated in adult patients for the treatment of complicated urinary tract infections, including pyelonephritis, caused by certain Gram-negative microorganisms, and is indicated, in combination with metronidazole, in adult patients for the treatment of complicated intra-abdominal infections caused by certain Gram-negative and Gram-positive microorganisms. Based on these","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:03+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/","name":"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-09-11T05:45:00+00:00","dateModified":"2025-11-07T06:27:03+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zerbaxa-ceftolozane-and-tazobactam-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in-pivotal-phase-3-study-of-adult-patients-with-hospital-acquired-bacterial-pn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s ZERBAXA\u00ae (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0b1ce6d9-7f8e-4a0a-a7d6-136954f57535","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-ZERBAXA-ceftolozane-and-tazobactam-Met-Primary-Endpoints-of-Non-Inferiority-Compared-to-Meropenem-in-Pivotal-Phase-3-Study-of--BEY0Y.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745667\/revisions"}],"predecessor-version":[{"id":3675015,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745667\/revisions\/3675015"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745667"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}